Navigation Links
VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
Date:11/26/2007

BASKING RIDGE, N.J., Nov. 26 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals (OTC Bulletin Board: VQPH) today announced the initiation of a Phase IIa study of Lenocta(TM) (sodium stibogluconate), a novel protein tyrosine phosphatase inhibitor, in combination with interferon alpha, an immune stimulant approved for the treatment of hepatitis C, hepatitis B and a number of cancers. The open-label Phase IIa study is designed to enroll at least 12 more patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGO )

The Phase IIa trial will evaluate the clinical efficacy and biological effectiveness of Lenocta at the highest tolerable dose in combination with interferon alpha in patients with advanced-stage solid tumors.

"We have reached a significant milestone in the development of Lenocta as a potential cancer therapy with the initiation of this trial," said Michael D. Becker, President and Chief Executive Officer of VioQuest Pharmaceuticals. "We will continue to advance our portfolio of novel compounds for various cancer indications into clinical development, the goal of this drug development organization."

Razelle Kurzrock M.D., Professor of Medicine Chair, Department of Investigational Cancer Therapeutics at The University of Texas M.D. Anderson Cancer Center is the lead principal investigator for the study, while Aung Naing M.D. of the same institution and Claire Verschraegen M.D. of The University of New Mexico Cancer Center are participating co-principal investigators.

Data from the recently concluded Phase I trial for Lenocta demonstrated pharmacodynamic activity in some solid tumors as demonstrated by increases in the activities of natural killer cells, CD8 and type II dendritic cells.

About Lenocta

Lenocta, a pentavalent antimonial originally used for the treatment of the parasitic disease leishmaniasis, is an inhibitor of multiple protein tyrosine phosphatases (PTPases), specifically the src homology PTPase (SHP-1 & SHP-2) and PTP1B. Lenocta has also been demonstrated to augment cytokine signaling and responses in hemopoietic cell lines, which can enhance the body's immune system. Preclinical testing of Lenocta has demonstrated anti-tumor activity against a wide spectrum of cancers.

About PTPases

The protein tyrosine phosphatase superfamily of enzymes functions in a coordinated manner with protein tyrosine kinases to control signaling pathways that underlie a broad spectrum of fundamental physiological processes and represent a new class of therapeutic targets. The PTPases SHP-1 and SHP-2 modulate progenitor cell development, cellular growth, tissue inflammation, cellular chemotaxis, and directly control cell survival involving oxidative stress pathways. SHP-1 and SHP-2 are fundamental for the function of several growth factor and metabolic pathways with far reaching implications for disease pathways and disorders such as diabetes, neurodegeneration, and cancer.

About VioQuest Pharmaceuticals

VioQuest focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action primarily for oncology and infectious diseases. VioQuest has three targeted drug candidates in clinical development: VQD-002 which inhibits Akt, a member of the serine/threonine-specific protein kinase family that is amplified, overexpressed, and/or activated in prostate, breast, ovarian, colorectal, pancreatic, and hematologic cancers; Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases SHP-1, SHP-2, and PTP1B that has demonstrated clinical and biological activity in solid tumors; and Xyfid(TM), a topical therapy which is being developed for the treatment and prevention of chemotherapy-induced Hand-Foot Syndrome (HFS). VioQuest anticipates commencing Phase II trials for VQD-002, and Xyfid in the first half of 2008. In addition, VioQuest and the U.S. Army are planning to submit a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) in 2008 for Lenocta for the treatment of leishmaniasis.

Further information about VioQuest can be found at http://www.vioquestpharm.com.

This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These forward-looking statements concern the timing, progress and results of the clinical development, regulatory processes, and potential clinical trial initiations of Lenocta. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. These statements are subject to various risks and uncertainties and include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM), will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Contact information:

Michael Becker

President and Chief Executive Officer

908-766-4400 ext. 115

Michael.becker@vioquestpharm.com

Brian Lenz

Chief Financial Officer

908-766-4400 ext. 117

Brian.lenz@vioquestpharm.com

Lisa Lindberg

VP, Investor Relations and Corporate Communications

908-766-4400 ext. 116

Lisa.lindberg@vioquestpharm.com


'/>"/>
SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
(Date:6/24/2016)... ... 2016 , ... Advanced Plastic Surgery Institute ( http://www.advancedplasticsurgeryinstitute.com ), ... official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns the practice, ... says the decision to support the pageant in an official capacity is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Southern Illinois ... are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy ... Gateway Convention Center in Collinsville. , They expect to treat approximately ...
(Date:6/24/2016)... Austin, TX (PRWEB) , ... June 24, 2016 , ... ... laude graduate, joins Evans Dermatology in the South Lamar location as of July 13, ... Texas Southwestern Medical School. As a medical student, she regularly volunteered at the Agape ...
Breaking Medicine News(10 mins):